This invention is directed to sorbitol dehydrogenase inhibitory compounds of
the formula I,
##STR1##
wherein R1, R2 and R3 are as defined in
the specification. This invention is also directed to pharmaceutical compositions
containing those compounds and methods of treating or preventing diabetic complications,
particularly diabetic neuropathy, diabetic nephropathy, diabetic microangiopathy,
diabetic macroangiopathy and diabetic cardiomyopathy by administering such compounds
to a mammal suffering from diabetes and therefore at risk for developing such complications.
This invention is also directed to pharmaceutical compositions comprising a combination
of a compound of formula I of this invention with an aldose reductase inhibitor
and to methods of treating or preventing diabetic complications therewith. This
invention is also directed to pharmaceutical compositions comprising a combination
of a compound of formula I of this invention with an NHE-1 inhibitor and to methods
of treating cardiomyopathy and other heart-related problems therewith. This invention
is also directed to certain intermediates used in the synthesis of the compounds
of formula I and to processes for preparing those intermediates.
